Aussie Nurses Allegedly Paid To Find Patients For Merck’s Vioxx, Court Told
This article was originally published in PharmAsia News
Executive SummaryAustralian nurses were allegedly paid by U.S.-based Merck and its Australian subsidiary, Merck, Sharp and Dohme to find prospective patients for the Vioxx (rofecoxib) anti-arthritis drug. That revelation was presented in a continuing class-action suit against the drug maker. The court was told Merck paid the nurses to get a physician's permission to go through his patient records and interview patients about their condition and pain management. Earlier, the court heard that pharmacists were paid by Merck to recommend to patients they take Vioxx instead of other drugs, such as paracetamol. (Click here for more
You may also be interested in...
Lannett’s Phase I trial for biosimilar insulin glargine has met “all primary endpoints,” the company has announced. The rival to Sanofi’s Lantus is being developed by Lannett with partner HEC through a deal for which financial details have just been revealed.
Sanofi Consumer Healthcare is to operate as a standalone unit in a move which is being viewed as a prelude to a potential spin-off. High profile prescription-to-OTC switches are a priority for the revamped business.
Data integrity issues were raised in many warning letters to active pharmaceutical ingredient manufacturers over the past four years.